Bydureon
AstraZeneca’s once-weekly auto-injector Bydureon BCise wins EU approval in type 2 diabetes
August 30, 2018Research and Development, Sales and Marketing AstraZeneca, Bydureon, EU, Europe, diabetes, pharma, type 2 diabetes
AstraZeneca has announced that its auto-injector Bydureon BCise (exenatide 2mg prolonged-release suspension) has been approved by the European Commission for …
Europe grants Eperzan licence
March 27, 2014Sales and Marketing Bydureon, GSK, diabetes, eperzan, lilly
The European Commission has granted marketing authorisation to GlaxoSmithKline’s new diabetes treatment Eperzan – setting the manufacturer on a collision …
Amylin withheld safety data, says FDA
June 27, 2012Research and Development, Sales and Marketing Amylin, Bydureon, Byetta, FDA, lilly
The US medicines regulator says Amylin held back data relating to the safety of its diabetes drug Bydureon. The allegation …
GSK’s diabetes drug misses goal
April 4, 2012Research and Development, Sales and Marketing Bydureon, GSK, Victoza, albiglutide, diabetes
GlaxoSmithKline has insisted its new long-acting Type 2 diabetes drug albiglutide remains on course for filing following topline results from …
Amylin dismisses BMS acquisition deal
March 30, 2012Manufacturing and Production, Sales and Marketing Amylin, BMS, Bydureon, diabetes, lilly
Amylin Pharmaceuticals has rebuffed a $3.5 billion unsolicited takeover bid from Bristol-Myers Squibb, according to reports. Shares in Amylin rose …
Amylin to pay up to $1.6 billion to sever ties with Lilly
November 8, 2011Research and Development, Sales and Marketing Amylin, Bydureon, Byetta, R&D, lilly
Amylin will pay up to $1.6 billion to end its diabetes pact with Lilly after a difficult year for the …
NICE recommends Lilly’s long-acting Bydureon
October 18, 2011Sales and Marketing Bydureon, NICE, diabetes
NICE has recommended Eli Lilly’s long-acting diabetes drug Bydureon after the failure of oral treatments. Bydureon (exenatide) – a long-acting …
FDA questions delay long-acting Byetta
March 17, 2010Manufacturing and Production Bydureon, Byetta, Syncria, Victoza
A once-weekly formulation of Eli Lilly and Amylin Pharmaceuticals’ blockbuster diabetes medication Byetta has hit a manufacturing hurdle en route …
Latest content
FibroFind appoints Lee Borthwick as CEO
